🇺🇸 FDA
Patent

US 8828717

Framework residue substituted humanized COL-1 antibodies and their use

granted A61KA61K2039/505A61P

Quick answer

US patent 8828717 (Framework residue substituted humanized COL-1 antibodies and their use) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Sep 09 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K2039/505, A61P, A61P35/00